000278796 001__ 278796
000278796 005__ 20250604100731.0
000278796 0247_ $$2doi$$a10.1136/bmjopen-2024-096162
000278796 0247_ $$2pmid$$apmid:40398955
000278796 037__ $$aDZNE-2025-00632
000278796 041__ $$aEnglish
000278796 082__ $$a610
000278796 1001_ $$aRocke, Merle$$b0
000278796 245__ $$aNeuromodulation through brain stimulation-assisted cognitive training in patients with post-chemotherapy subjective cognitive impairment (Neuromod-PCSCI) after breast cancer: study protocol for a double-blinded randomised controlled trial.
000278796 260__ $$aLondon$$bBMJ Publishing Group$$c2025
000278796 3367_ $$2DRIVER$$aarticle
000278796 3367_ $$2DataCite$$aOutput Types/Journal article
000278796 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748946707_16670
000278796 3367_ $$2BibTeX$$aARTICLE
000278796 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278796 3367_ $$00$$2EndNote$$aJournal Article
000278796 520__ $$aBreast cancer is the most common form of cancer in women. A considerable number of women with breast cancer who have been treated with chemotherapy subsequently develop neurological symptoms such as concentration and memory difficulties (also known as 'chemobrain'). Currently, there are no validated therapeutic approaches available to treat these symptoms. Cognitive training holds the potential to counteract cognitive impairment. Combining cognitive training with concurrent transcranial direct current stimulation (tDCS) could enhance and maintain the effects of this training, potentially providing a new approach to treat post-chemotherapy subjective cognitive impairment (PCSCI). With this study, we aim to investigate the effects of multi-session tDCS over the left dorsolateral prefrontal cortex in combination with cognitive training on cognition and quality of life in women with PCSCI.The Neuromod-PCSCI trial is a monocentric, randomised, double-blind, placebo-controlled study. Fifty-two women with PCSCI after breast cancer therapy will receive a 3-week tDCS-assisted cognitive training with anodal tDCS over the left dorsolateral prefrontal cortex (target intervention), compared with cognitive training plus sham tDCS (control intervention). Cognitive training will consist of a letter updating task. Primary outcome will be the performance in an untrained task (n-back task) after training. In addition, feasibility, safety and tolerability, as well as quality of life and performance in additional untrained tasks will be investigated. A follow-up visit will be performed 1 month after intervention to assess possible long-term effects. In an exploratory approach, structural and functional MRI will be acquired before the intervention and at post-intervention to identify possible neural predictors for successful intervention.Ethical approval was granted by the ethics committee of the University Medicine Greifswald (BB236/20). Results will be available through publications in peer-reviewed journals and presentations at national and international conferences.ClinicalTrials.gov; NCT04817566, registered on 26 March 2021.
000278796 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278796 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278796 650_7 $$2Other$$aCHEMOTHERAPY
000278796 650_7 $$2Other$$aCognition
000278796 650_7 $$2Other$$aQuality of Life
000278796 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000278796 650_2 $$2MeSH$$aHumans
000278796 650_2 $$2MeSH$$aBreast Neoplasms: drug therapy
000278796 650_2 $$2MeSH$$aFemale
000278796 650_2 $$2MeSH$$aTranscranial Direct Current Stimulation: methods
000278796 650_2 $$2MeSH$$aDouble-Blind Method
000278796 650_2 $$2MeSH$$aQuality of Life
000278796 650_2 $$2MeSH$$aRandomized Controlled Trials as Topic
000278796 650_2 $$2MeSH$$aCognitive Behavioral Therapy: methods
000278796 650_2 $$2MeSH$$aChemotherapy-Related Cognitive Impairment: therapy
000278796 650_2 $$2MeSH$$aChemotherapy-Related Cognitive Impairment: etiology
000278796 650_2 $$2MeSH$$aCognitive Dysfunction: therapy
000278796 650_2 $$2MeSH$$aCognitive Dysfunction: chemically induced
000278796 650_2 $$2MeSH$$aMiddle Aged
000278796 650_2 $$2MeSH$$aAdult
000278796 650_2 $$2MeSH$$aDorsolateral Prefrontal Cortex
000278796 650_2 $$2MeSH$$aPrefrontal Cortex
000278796 650_2 $$2MeSH$$aCognition
000278796 650_2 $$2MeSH$$aAntineoplastic Agents: adverse effects
000278796 650_2 $$2MeSH$$aCognitive Training
000278796 7001_ $$aKnochenhauer, Elena$$b1
000278796 7001_ $$aThams, Friederike$$b2
000278796 7001_ $$aAntonenko, Daria$$b3
000278796 7001_ $$00000-0001-7709-3311$$aFromm, Anna Elisabeth$$b4
000278796 7001_ $$aJansen, Nora$$b5
000278796 7001_ $$aAziziaram, Samaneh$$b6
000278796 7001_ $$aGrittner, Ulrike$$b7
000278796 7001_ $$aSchmidt, Sein$$b8
000278796 7001_ $$aVogelgesang, Antje$$b9
000278796 7001_ $$aBrakemeier, Eva-Lotta$$b10
000278796 7001_ $$0P:(DE-2719)2812683$$aFlöel, Agnes$$b11$$eLast author
000278796 773__ $$0PERI:(DE-600)2599832-8$$a10.1136/bmjopen-2024-096162$$gVol. 15, no. 5, p. e096162 -$$n5$$pe096162$$tBMJ open$$v15$$x2044-6055$$y2025
000278796 8564_ $$uhttps://pub.dzne.de/record/278796/files/DZNE-2025-00632.pdf$$yOpenAccess
000278796 8564_ $$uhttps://pub.dzne.de/record/278796/files/DZNE-2025-00632.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278796 909CO $$ooai:pub.dzne.de:278796$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000278796 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812683$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000278796 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278796 9141_ $$y2025
000278796 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000278796 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278796 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMJ OPEN : 2022$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:10:16Z
000278796 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:10:16Z
000278796 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278796 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-01-24T13:10:16Z
000278796 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000278796 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000278796 9201_ $$0I:(DE-2719)5000081$$kAG Flöel$$lDementia Prevention – Mechanisms and Clinical Implementation$$x0
000278796 980__ $$ajournal
000278796 980__ $$aVDB
000278796 980__ $$aUNRESTRICTED
000278796 980__ $$aI:(DE-2719)5000081
000278796 9801_ $$aFullTexts